Guselkumab Achieves Clinical, Endoscopic Remission in Ulcerative Colitis
First-time data from the Phase 3 QUASAR Maintenance Study revealed patients with moderately to severely active ulcerative colitis (UC) met the primary endpoint of clinical remission with subcutaneous guselkumab (TREMFYA) treatment.1 Presented at Digestive …